Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...

Sarah Benn loses suspension appeal The retired GP and climate activist Sarah Benn lost her High Court appeal against a misconduct finding and suspension by a medical practitioners’ tribunal over her ...

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

as well as Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia – both autologous cell therapies that seek to address the underlying genetic defect in SCD. Adakveo has, however ...

“We are pleased to have reached this new agreement that ensures both eligible SCD and TDT patients can now be treated with Casgevy, recognizing the value a one-time treatment can provide to ...

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.